Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

NCT07674524 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer (NSCLC)
Hyperlipidemia
ALK Gene Mutation
ALK-positive

Interventions

DRUG: For Part A - Observational Cohort:
DRUG: Part B: Intensive Lipid-Lowering Group
DRUG: For Part B - Intensive Group

Sponsor

Sun Yat-sen University

Collaborators

[object Object]